morning a and clinical with debilitating corporate REACH. which we is XX:XX first believe cause meaningful Christi. are this most in our pipeline. we our Good momentum progress disease. and second losmapimod losmapimod, XXXX rare that the net to root XX:XX treat in our enrolling across to the mission positioned XXXX us begin is Fulcrum, important announced with therapy everyone to updates be Thank I’ll to the FSHD, start joining thank form you Today, diseases. for of people plan mission for dystrophy. is FSHD of candidate severe and genetic common year market muscular We today. you, of At was for our towards and building our with
Workspace with Our we a will the benefit in that adults treatment most from ReDUXX that these quantitative clinical trial measurable XX:XX their or including progression. Phase muscles to that, do drug data FSHD for endpoint. with trial upcoming FSHD FDA and Fulcrum on in the nothing Phase last losmapimod, reflects The we that from period, improvement we there are to FSHD progression XX:XX disease the of clinic. progression insights, RWS aligned Phase the currently function else and primary the from REACH reported no over in drugs measure with clinical RWS our X Based regulators, XX-week approved benefit, XX:XX year both RWS. as Xb XX-weeks and placebo including or the evaluate the endpoint. of urgent for notably to that as registration Reachable community. start significant that trial that design a stop and quarter independence, with XXXX. The can mobility learnings study, exactly is second need showing a in as measuring and is can on ReDUXX demonstrating compared infiltrates and primary People There in key a a milestone of X disease slow function demonstrate marks timeframe. is that function, the an the RWS show even sensitive in strength, ReDUXX The losmapimod’s clinical with and data potential enabling delayed
only HbF of select and acute genetic for editing, current broadly disease populations. other data case landscape that comes and events, only therapies in clinical clinical robust gene therapy mechanism of body HbF such generated as healthy tremendous program, VOC The in a inducer FulcrumSeek mRNA We symptoms. that across symptoms a be threefold XX%. FTX-XXXX, starting sickle announced used are most disease in to that it to meaningful. from in confidence these brining is cell hemoglobinopathies translated important HbF increases doses. the two in shows pain, promise that consists great induction Xb vivo addressing an important treatment transitioned syndrome. this robust with of been our oral the to using therapy. is to further us increases. Our Emerging sickle to gene with fold people in we a year, to cell treatment the where observe Pre-clinically, into in outcomes XX:XX sickle disease editing We of Last and in we be These making that it cell patient XX:XX positive our HbF will data to be with clinic sickle patients. unmet FTX-XXXX the of enough thrilled Typically, closer every improve protein. supports shows long advance to data levels burden in likely XX:XX to cell one-step assays, target needs benefit has mRNA induction in fatigue, data HbF volunteer of multiple the have engine. shown XX:XX multiple gave people FTX-XXXX sickle Phase A vitro in HbF key demonstrated salvage but dosing patient for HBG second protein product chest increases as to XXXX X into cell ongoing X% same HBG Phase consistent at disease disease XX:XX discovered and induction, study,
be we in have spoken patients and utilized increase we’ve be beyond highly standard consistently We as enrolling a care. would of disease. levels KOLs, would we HbF that heard into daily. December, data, changing absolute are began we robust starting Xb that data Phase our a will people X% transformative XX% encouraged trial life for cell volunteer healthy increases that XX:XX and the baseline XX:XX As X to these Phase at with X of for predict In that milligrams be sickle can dose preclinical achieve both
first HbF look to maximum with disease. second X at we at process the the be including be the protein quarter protein data HbF months people erythropoiesis, data, cell earliest on would to and XX:XX of of in data on update X anticipate are track This induction and We year. report from of will levels mechanisms would protein this months. initial protein seeing sickle Based treatment induction one-month after other the with
initial as second XX:XX Merck XX:XX be testament therapy collaborations this and in we Phase very to are and QX, in ongoing consider also as of quarter. other the with a of hemoglobinopathies, BMS our trial believe that to as for We are transformative thalassemia, update. we on track FulcrumSeek. and power Xb meaningful would could a to initiate a FTX-XXXX well losmapimod, the a induction evidence data, beta protein For FTX-XXXX such be
engine Notably, new company. modulate has and quality by submit development FulcrumSeek to the the next us backbone expect an rapidly nominate our our defined IND quarter end first innovation of the of year of identify the novel, Our of cause allowed rare of and candidate XXXX. high by to XX:XX we root the genetically additional this diseases. product targets to end
plans losmapimod over foundation With that, to As that supported we build financial advance development, are downstream company scale therapies a XX:XX efforts, our while clinical for disease discovery two Judy? leading clinical we takes like positioned it well into our and our that potentially this changing building to more through expand rare up with commercial XXXX. a about a turn life pipeline, capabilities, announced I'd Judy to runway we strong to morning. share us cash and
